Evidence map›Paper›PMID 31492655›Full record

ArticleCell host & microbe2019

CRISPR-Cas System of a Prevalent Human Gut Bacterium Reveals Hyper-targeting against Phages in a Human Virome Catalog.

Paola Soto-Perez, Jordan E Bisanz, Joel D Berry, Kathy N Lam, Joseph Bondy-Denomy, Peter J Turnbaugh

Open access · bronzeAbstract read
In one paragraph

Article in Cell host & microbe, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 79 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Research square · 2026
    Article
  6. bioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Journal of the American Chemical Society · 2025
    Article
  15. Phage diversity in One Health.Essays in biochemistry · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Paola Soto-PerezDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Jordan E BisanzDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Joel D BerryDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Kathy N LamDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Joseph Bondy-DenomyDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: joseph.bondy-denomy@ucsf.edu.
Peter J TurnbaughDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA. Electronic address: peter.turnbaugh@ucsf.edu.
University of California, San Francisco · USQB3 · US

Funding

Predicting and preventing drug metabolism by the human gut microbiomeR01HL122593 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Peter James Turnbaugh · 2016 to 2026
$5.7M
Discovering New Roles for CRISPR-Cas in Bacterial PathogenesisDP5OD021344 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BONDY-DENOMY, JOSEPH · 2015 to 2019
$2.1M
NHLBI NIH HHS R01 HL122593NIH HHS DP5 OD021344
6 · The paper itself

Abstract

Bacteriophages are abundant within the human gastrointestinal tract, yet their interactions with gut bacteria remain poorly understood, particularly with respect to CRISPR-Cas immunity. Here, we show that the type I-C CRISPR-Cas system in the prevalent gut Actinobacterium Eggerthella lenta is transcribed and sufficient for specific targeting of foreign and chromosomal DNA. Comparative analyses of E. lenta CRISPR-Cas systems across (meta)genomes revealed 2 distinct clades according to cas sequence similarity and spacer content. We assembled a human virome database (HuVirDB), encompassing 1,831 samples enriched for viral DNA, to identify protospacers. This revealed matches for a majority of spacers, a marked increase over other databases, and uncovered "hyper-targeted" phage sequences containing multiple protospacers targeted by several E. lenta strains. Finally, we determined the positional mismatch tolerance of observed spacer-protospacer pairs. This work emphasizes the utility of merging computational and experimental approaches for determining the function and targets of CRISPR-Cas systems.

Indexed as

CRISPR-Cas SystemsActinobacteriaBacteriaBacteriophagesBase SequenceDatabases, GeneticDNA, BacterialDNA, ViralGastrointestinal TractGenome, BacterialGenome, ViralHumansMetagenomicsMicrobiotaSequence Analysis, DNADNA, BacterialDNA, ViralbacteriophageCRISPR-Cas systemsCRISPR spacerheterologous expressionhuman microbiomehyper-targetingvirome

Identifiers

PMID31492655
PMCPMC6936622
OpenAlexW2972142394

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.